Rapid, Single-Step Monitoring of Monoclonal Antibody Bioavailability by Using a TNF-α-Based Multiepitope DNA Nanoswitch
Open Access
- 8 April 2025
- journal article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (15) , 8195-8201
Abstract
Therapeutic drug monitoring (TDM) is increasingly valuable for tailoring personalized therapy, particularly in managing chronic inflammatory diseases where overtreatment can cause significant side effects. Monoclonal antibodies (mAbs), a primary therapeutic approach for these conditions, face challenges from antidrug antibodies (ADAs), which can reduce mAb bioavailability and efficacy. To address these issues, we utilized Tumor Necrosis Factor α (TNF-α) as a binding moiety in a fluorescence-based programmable nanosensor within the NanoHYBRID (NH) platform developed by Ulisse Biomed S.p.A. By directly conjugating TNF-α to DNA probes, we developed a rapid, homogeneous, affinity-based assay capable of detecting multiple mAbs targeting distinct epitopes on the same protein. This NH platform effectively detected therapeutic concentrations of clinically relevant mAbs, such as Infliximab, Adalimumab, and Golimumab, in blood serum samples in a one-step process, bypassing the need for time-intensive washing steps. Moreover, the NH sensor exhibited heightened sensitivity to the presence of ADA, which impacted drug quantification, indicating its utility for monitoring bioavailable mAb levels. Compared to ELISA, the NH platform demonstrated superior sensitivity to ADAs, suggesting its potential as a highly specific, modular solution for TDM. This modular design allows the NH platform to create multiepitope nanosensors capable of measuring bioavailable mAbs in a single step.Keywords
Funding Information
- Ministero dell?Istruzione, dell?Universit? e della Ricerca (D53D23009090001-2022FPYZ2N-958)
- European Social Fund Plus
This publication has 36 references indexed in Scilit:
- Design of Specific Nucleic Acid‐Based Biosensors for Protein Binding ActivityAnalysis & Sensing, 2022
- Utility, promise, and limitations of liquid chromatography‐mass spectrometry‐based therapeutic drug monitoring in precision medicineJournal of Mass Spectrometry, 2021
- Harnessing Effective Molarity to Design an Electrochemical DNA‐based Platform for Clinically Relevant Antibody DetectionAngewandte Chemie International Edition, 2020
- Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumabProtein Science, 2018
- Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysisAnalytical Biochemistry, 2018
- Tumor Necrosis Factor Signaling Pathways2016
- Bioavailability and bioequivalence in drug developmentWIREs Computational Statistics, 2014
- Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseasesCurrent Opinion in Pharmacology, 2010
- Immunogenicity of Anti-TNF-α Agents in Autoimmune DiseasesClinical Reviews in Allergy & Immunology, 2009
- TNF? and the TNF receptor superfamily: Structure-function relationship(s)Microscopy Research and Technique, 2000